Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NBIX
stocks logo

NBIX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
805.46M
+28.32%
2.428
+43.68%
773.97M
+35.17%
1.986
+183.76%
838.22M
+21.92%
2.191
+32.76%
Estimates Revision
The market is revising Upward the revenue expectations for Neurocrine Biosciences, Inc. (NBIX) for FY2025, with the revenue forecasts being adjusted by 2.4% over the past three months. During the same period, the stock price has changed by 9.84%.
Revenue Estimates for FY2025
Revise Upward
up Image
+2.4%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+2.26%
In Past 3 Month
Stock Price
Go Up
up Image
+9.84%
In Past 3 Month
Wall Street analysts forecast NBIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NBIX is 176.67 USD with a low forecast of 146.00 USD and a high forecast of 203.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
23 Analyst Rating
Wall Street analysts forecast NBIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NBIX is 176.67 USD with a low forecast of 146.00 USD and a high forecast of 203.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
21 Buy
2 Hold
0 Sell
Strong Buy
Current: 154.220
sliders
Low
146.00
Averages
176.67
High
203.00
Current: 154.220
sliders
Low
146.00
Averages
176.67
High
203.00
Morgan Stanley
Sean Laaman
Overweight
downgrade
$178 -> $173
2025-11-11
Reason
Morgan Stanley
Sean Laaman
Price Target
$178 -> $173
2025-11-11
downgrade
Overweight
Reason
Morgan Stanley analyst Sean Laaman lowered the firm's price target on Neurocrine to $173 from $178 and keeps an Overweight rating on the shares after the company reported that its Phase 2 study evaluating the efficacy, safety and tolerability of investigational compound NBI-1070770 in adults with major depressive disorder did not meet the primary endpoint. The firm, which removed NBI-'770 from its earnings model, says the Phase 2 "disappointment" positions osavampator as the only shot on goal in MDD.
JPMorgan
Anupam Rama
maintain
$171 -> $179
2025-11-03
Reason
JPMorgan
Anupam Rama
Price Target
$171 -> $179
2025-11-03
maintain
Reason
JPMorgan analyst Anupam Rama raised the firm's price target on Neurocrine to $179 from $171 and keeps an Overweight rating on the shares.
Mizuho
Neutral
maintain
$145 -> $146
2025-10-29
Reason
Mizuho
Price Target
$145 -> $146
2025-10-29
maintain
Neutral
Reason
Mizuho raised the firm's price target on Neurocrine to $146 from $145 and keeps a Neutral rating on the shares.
RBC Capital
Outperform
maintain
$156 -> $160
2025-10-29
Reason
RBC Capital
Price Target
$156 -> $160
2025-10-29
maintain
Outperform
Reason
RBC Capital raised the firm's price target on Neurocrine to $160 from $156 and keeps an Outperform rating on the shares after its Q3 earnings beat. The company's Crenessity launch continues to impress, while Ingrezza came in ahead of expectations albeit with some pricing tradeoffs, the analyst tells investors in a research note. RBC adds that there could be some share volatility into the upcoming Austedo IRA announcement, but also notes that this presents a buying opportunity as the impact should be "manageable".
Stifel
Buy
maintain
$174 -> $183
2025-10-29
Reason
Stifel
Price Target
$174 -> $183
2025-10-29
maintain
Buy
Reason
Stifel raised the firm's price target on Neurocrine to $183 from $174 and keeps a Buy rating on the share following a Q3 report the firm says was "highlighted by a clear Ingrezza beat, as well as another substantial beat on Crenessity." The firm, which notes it previously raised its peak sales estimate for Crenessity in Q2, is again raising near-term estimates following "another exemplary quarter," the analyst added.
Needham
Needham
Buy
maintain
$170 -> $184
2025-10-29
Reason
Needham
Needham
Price Target
$170 -> $184
2025-10-29
maintain
Buy
Reason
Needham raised the firm's price target on Neurocrine to $184 from $170 and keeps a Buy rating on the shares. The company reported a strong Q3, with EPS topping consensus thanks to better-than-expected product performance, the analyst tells investors in a research note. The management is again expanding its sales force by about 30% to continue driving Ingrezza volume growth ahead of IRA- related pricing pressure for Austedo starting 2027 and to broaden endocrinologist reach for Crenessity, the firm added, noting that Neurocrine remains well positioned to drive shareholder value with two scaled commercial assets and a deep, advancing pipeline.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Neurocrine Biosciences Inc (NBIX.O) is 16.99, compared to its 5-year average forward P/E of 22.10. For a more detailed relative valuation and DCF analysis to assess Neurocrine Biosciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
22.10
Current PE
16.99
Overvalued PE
27.67
Undervalued PE
16.53

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
22.26
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
29.13
Undervalued EV/EBITDA
15.39

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
5.78
Current PS
0.00
Overvalued PS
6.96
Undervalued PS
4.60
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

NBIX News & Events

Events Timeline

(ET)
2025-11-10
16:12:25
Neurocrine reports that Phase 2 trial of NBI-1070770 failed to achieve primary endpoint.
select
2025-10-29 (ET)
2025-10-29
11:13:28
RBC Capital Views Neurocrine's Decline After 'Strong Quarter' as a Buying Opportunity
select
2025-10-29
11:11:36
Neurocrine Shares Decline Following DOJ's Investigative Request for Ingrezza
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
05:18 AMYahoo Finance
Neurocrine Biosciences Executive Offloads Shares Valued at $2,289,083, Per Recent SEC Disclosure

  • Director's Stock Sale: Gary A Lyons, the Director of Neurocrine Biosciences, sold 15,000 shares of the company's stock on December 03, 2025.

  • Company Overview: Neurocrine Biosciences (NBIX) is a biopharmaceutical company focused on developing treatments for neurological and endocrine diseases.

[object Object]
Preview
6.5
11-28NASDAQ.COM
Reasons for Growth Investors to Consider Buying Neurocrine (NBIX) at This Time

  • Growth Investing Overview: Growth investors seek stocks with above-average financial growth, but these stocks come with higher risks and volatility. Identifying strong growth stocks can be challenging.

  • Neurocrine Biosciences Recommendation: Neurocrine Biosciences (NBIX) is highlighted as a strong growth stock due to its favorable Growth Score and top Zacks Rank, indicating potential for solid returns.

  • Key Growth Metrics: Neurocrine's projected EPS growth of 99.6% this year and year-over-year cash flow growth of 35.4% significantly surpass industry averages, making it an attractive option for growth investors.

  • Earnings Estimate Revisions: The upward trend in earnings estimate revisions for Neurocrine, with a 15.4% increase in the current-year estimates, further supports its strong growth potential and Zacks Rank #1 status.

[object Object]
Preview
3.5
11-24Newsfilter
Neurocrine Publishes Review on INGREZZA, Highlighting Unique Efficacy
  • Review Publication: Neurocrine Biosciences has published a comprehensive narrative review in CNS Spectrums, consolidating over a decade of clinical research on VMAT2 inhibitors. This review emphasizes the unique attributes of INGREZZA, including selective VMAT2 targeting and simplified dosing, aimed at aiding healthcare providers in making optimal treatment decisions.
  • Clinical Data Support: The review presents robust clinical data for INGREZZA across diverse patient populations, particularly noting therapeutic responses at the lowest available dose of 40 mg. These findings indicate significant efficacy and favorable tolerability of INGREZZA in treating tardive dyskinesia.
  • Importance of Drug Selection: The study highlights that while both VMAT2 inhibitors target the same receptor, their pharmacologic properties and clinical applications differ, underscoring the importance of drug selection based on each medication's unique mechanism and safety profile. This insight is crucial for clinicians treating tardive dyskinesia.
  • Long-term Efficacy Evidence: The review includes results from double-blind, placebo-controlled trials, providing evidence of INGREZZA's sustained efficacy in long-term treatment. These findings offer reliable treatment options for patients, particularly in chronic conditions requiring ongoing management.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Neurocrine Biosciences Inc (NBIX) stock price today?

The current price of NBIX is 154.22 USD — it has increased 1.49 % in the last trading day.

arrow icon

What is Neurocrine Biosciences Inc (NBIX)'s business?

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.

arrow icon

What is the price predicton of NBIX Stock?

Wall Street analysts forecast NBIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NBIX is 176.67 USD with a low forecast of 146.00 USD and a high forecast of 203.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Neurocrine Biosciences Inc (NBIX)'s revenue for the last quarter?

Neurocrine Biosciences Inc revenue for the last quarter amounts to 794.90M USD, increased 27.78 % YoY.

arrow icon

What is Neurocrine Biosciences Inc (NBIX)'s earnings per share (EPS) for the last quarter?

Neurocrine Biosciences Inc. EPS for the last quarter amounts to 2.04 USD, increased 64.52 % YoY.

arrow icon

What changes have occurred in the market's expectations for Neurocrine Biosciences Inc (NBIX)'s fundamentals?

The market is revising Upward the revenue expectations for Neurocrine Biosciences, Inc. (NBIX) for FY2025, with the revenue forecasts being adjusted by 2.4% over the past three months. During the same period, the stock price has changed by 9.84%.
arrow icon

How many employees does Neurocrine Biosciences Inc (NBIX). have?

Neurocrine Biosciences Inc (NBIX) has 1800 emplpoyees as of December 05 2025.

arrow icon

What is Neurocrine Biosciences Inc (NBIX) market cap?

Today NBIX has the market capitalization of 15.38B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free